Argos Therapeutics Inc. (ARGS) Downgraded by Zacks Investment Research
Argos Therapeutics Inc. (NASDAQ:ARGS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “
A number of other research firms have also commented on ARGS. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. FBR & Co reaffirmed a “buy” rating on shares of Argos Therapeutics in a research report on Tuesday, June 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $11.50.
Shares of Argos Therapeutics (NASDAQ:ARGS) traded up 1.03% during trading on Tuesday, hitting $4.90. 85,930 shares of the stock were exchanged. Argos Therapeutics has a 52 week low of $1.61 and a 52 week high of $13.97. The firm’s market capitalization is $201.86 million. The firm has a 50 day moving average price of $4.87 and a 200 day moving average price of $5.92.
Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Analysts forecast that Argos Therapeutics will post ($1.56) EPS for the current fiscal year.
In other news, major shareholder International S. Pharmstandard bought 16,977 shares of the firm’s stock in a transaction on Thursday, September 1st. The shares were purchased at an average cost of $4.78 per share, with a total value of $81,150.06. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder International S. Pharmstandard bought 75,474 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was purchased at an average cost of $4.24 per share, for a total transaction of $320,009.76. The disclosure for this purchase can be found here. 61.64% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new stake in Argos Therapeutics during the second quarter worth $137,000. Schwab Charles Investment Management Inc. bought a new stake in Argos Therapeutics during the second quarter worth $137,000. KCG Holdings Inc. bought a new stake in Argos Therapeutics during the second quarter worth $163,000. BlackRock Investment Management LLC increased its stake in Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 37,818 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 3,559 shares during the last quarter. Institutional investors own 11.05% of the company’s stock.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.